CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.005
EU - Europa 849
AS - Asia 535
OC - Oceania 17
AF - Africa 7
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.420
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 997
CN - Cina 383
GB - Regno Unito 244
SE - Svezia 104
IT - Italia 99
FR - Francia 96
IE - Irlanda 89
RU - Federazione Russa 86
DE - Germania 72
SG - Singapore 65
HK - Hong Kong 28
FI - Finlandia 22
AU - Australia 17
VN - Vietnam 17
IN - India 11
KR - Corea 8
UA - Ucraina 7
JP - Giappone 6
TR - Turchia 6
BE - Belgio 5
CA - Canada 5
NL - Olanda 5
PL - Polonia 5
TG - Togo 5
EU - Europa 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
MX - Messico 2
RO - Romania 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
BR - Brasile 1
BY - Bielorussia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
ID - Indonesia 1
IR - Iran 1
KH - Cambogia 1
LT - Lituania 1
LV - Lettonia 1
MY - Malesia 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
SM - San Marino 1
Totale 2.420
Salva come PNG Salva come JPEG
Città #
Chandler 293
Southend 229
Beijing 115
Dublin 89
Woodbridge 83
Ann Arbor 48
Ashburn 43
Wilmington 41
Lawrence 40
Princeton 40
Singapore 38
Jinan 34
Shenyang 32
Jacksonville 30
Hong Kong 28
Sindelfingen 26
Nanjing 25
New York 24
Verona 20
Falls Church 13
Hebei 12
Zhengzhou 12
Tianjin 11
Perth 10
Redmond 10
Taiyuan 10
Changsha 9
Dong Ket 9
Guangzhou 9
Redwood City 9
Dallas 8
Nanchang 8
Seoul 8
Bologna 7
Houston 7
Los Angeles 7
Norwalk 7
Taizhou 7
Haikou 6
Helsinki 6
Kent 6
Ningbo 6
Tokyo 6
Brussels 5
Chengdu 5
Düsseldorf 5
Lomé 5
Milan 5
San Francisco 5
Seattle 5
Bergamo 4
Fairfield 4
Washington 4
Boardman 3
Canberra 3
Cento 3
Delhi 3
Fremont 3
Fuzhou 3
Hangzhou 3
Jiaxing 3
Kochi 3
Melbourne 3
Palermo 3
Polska 3
Brescia 2
Caldiero 2
Cambridge 2
Chennai 2
Clearwater 2
Duncan 2
Florence 2
Lanzhou 2
Leawood 2
Munich 2
New Haven 2
Nuremberg 2
Nürnberg 2
Paris 2
Piacenza 2
Reggiolo 2
Shanghai 2
Tashkent 2
Toronto 2
Vancouver 2
Varese 2
Xi'an 2
Adliswil 1
Amsterdam 1
Athens 1
Austin 1
Bloomsbury 1
Brecon 1
Brno 1
Buenos Aires 1
Caronno Pertusella 1
Chester 1
Chicago 1
Costa Mesa 1
Cupertino 1
Totale 1.621
Salva come PNG Salva come JPEG
Nome #
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 122
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 119
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 112
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 104
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 96
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 87
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 86
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 84
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 80
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 79
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 78
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 77
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 76
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 75
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 71
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 67
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 62
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 59
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 57
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 57
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 57
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 56
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 53
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 52
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 51
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 49
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 47
Management of Chronic Myeloid Leukemia in Advanced Phase 46
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 43
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 41
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 40
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 39
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 34
Second cancers in MPN: Survival analysis from an international study 30
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 30
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 24
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 24
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 23
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 22
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 20
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 20
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 17
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 13
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 7
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 6
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 6
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 5
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 4
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 3
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 3
Totale 2.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.084
article - articoli 8.680
book - libri 0
conference - conferenze 2.404
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.168
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020248 0 0 0 4 24 30 0 9 28 55 60 38
2020/2021241 31 44 11 27 46 28 1 2 3 3 22 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/2025175 46 57 39 33 0 0 0 0 0 0 0 0
Totale 2.513